Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with P
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q1 2024 | PHENYLETHYL ALCOHOL | NASAL | SPRAY, METERED | 10mg | Correction | ||
| Q2 2024 | PHENYLETHYL ALCOHOL | NASAL | SPRAY, METERED | 2mg | Correction | ||
| Q1 2024 | POLYVINYL ALCOHOL | ORAL | CAPSULE, EXTENDED RELEASE | 6mg | Correction | ||
| Q2 2024 | POLYVINYL ALCOHOL | ORAL | CAPSULE, EXTENDED RELEASE | 3mg | Correction | ||
| Q1 2024 | POVIDONE | ORAL | CAPSULE, EXTENDED RELEASE | 120mg | Correction | ||
| Q2 2024 | POVIDONE | ORAL | CAPSULE, EXTENDED RELEASE | 56mg | Correction | ||
| Q1 2024 | PROSOLV | ORAL | TABLET, EXTENDED RELEASE | 791mg | Correction | ||
| Q2 2024 | PROSOLV ODT | ORAL | TABLET, EXTENDED RELEASE | 791mg | Correction | ||
| Q1 2024 | PROSOLV | ORAL | TABLET, ORALLY DISINTEGRATING | 240.07 mg | Correction | ||
| Q2 2024 | PROSOLV ODT | ORAL | TABLET, ORALLY DISINTEGRATING | 361mg | Correction | ||
| Q2 2024 | POLYETHYLENE GLYCOL 200 | ORAL | TABLET, EXTENDED RELEASE | NA | Deletion | ||
| Q2 2024 | POLYETHYLENE GLYCOL 4500 | ORAL | TABLET, COATED | NA | Deletion | ||
| Q2 2024 | POLYOXYL GLYCERYL STEARATE | TOPICAL | CREAM | 5.00 %w/w | Deletion | ||
| Q2 2024 | POVIDONE | TRANSDERMAL | SOLUTION | 2.00 %w/v | Deletion | ||
| Q1 2024 | POLOXAMER 407 | OPHTHALMIC | GEL | 0.20 %w/w | MDE Replacement | ||
| Q2 2024 | POLOXAMER 407 | OPHTHALMIC | GEL | 1mg | MDE Replacement | ||
| Q1 2024 | PROPYLPARABEN | TOPICAL | SOLUTION | 0.10 %w/v | MDE Replacement | ||
| Q2 2024 | PROPYLPARABEN | TOPICAL | SOLUTION | 24mg | MDE Replacement | ||
| Q1 2024 | PROSOLV | ORAL | TABLET, ORALLY DISINTEGRATING | 240.07 mg | MDE Replacement | ||
| Q2 2024 | PROSOLV ODT | ORAL | TABLET, ORALLY DISINTEGRATING | 361mg | MDE Replacement | ||
| Q1 2024 | PROSOLV 50 | ORAL | CAPSULE | 33.86 mg | MDE Replacement | ||
| Q2 2024 | PROSOLV 50 | ORAL | CAPSULE | 33mg | MDE Replacement | ||
| Q1 2024 | PROSOLV 90 | ORAL | CAPSULE | 50.78 mg | MDE Replacement | ||
| Q2 2024 | PROSOLV 90 | ORAL | CAPSULE | 50mg | MDE Replacement | ||
| Q1 2024 | PROSOLV 90 | SUBLINGUAL | TABLET | 18.70 mg | MDE Replacement | ||
| Q2 2024 | PROSOLV 90 | SUBLINGUAL | TABLET | 19mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: March 15, 2024
Database Last Updated: April 29, 2024